www.fdanews.com/articles/108184-mpex-starts-trial-of-cystic-fibrosis-drug
Mpex Starts Trial of Cystic Fibrosis Drug
July 1, 2008
Mpex Pharmaceuticals has begun a Phase II clinical study with MP-376 for the treatment of pulmonary infections in patients with cystic fibrosis (CF).
The drug is an aerosol formulation of levofloxacin, an antibiotic that fights against bacterial pathogens that can cause lower respiratory infections, Mpex said.
The study is expected to enroll 140 stable CF patients to evaluate the drug’s safety, tolerability and efficacy over 28 days.